Arash Babaei-Ghazani

Arash Babaei-Ghazani

Auto-generated profile, based on publicly available information

Arash Babaei-Ghazani

Neuromusculoskeletal Research Center, Department of Physical Medicine & Rehabilitation, School of Medicine, Iran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2019 in American Journal of Physical Medicine & Rehabilitation
Verified
Journal Article
Closed access
PRPeyman Roomizadeh
Peyman Roomizadeh
BEBina Eftekharsadat
Bina Eftekharsadat
AAAmin Abedini
Amin Abedini
SRSepideh Ranjbar-Kiyakalayeh
Sepideh Ranjbar-Kiyakalayeh
NYNaseh Yousefi
Naseh Yousefi
ABArash Babaei-Ghazani
Arash Babaei-Ghazani
Objective: The aim of the study was to investigate the overall estimates of cross-sectional areas of the median nerve measured by ultrasonography in accordance with the electrodiagnostic classification of carpal tunnel syndrome severity. Design: MEDLINE (PubMed), Embase (Ovid), and Web of Science were searched for studies reporting the median nerve cross-sectional area measured by ultrasonography for mild, moderate, and severe carpal tunnel syndrome based on electrodiagnostic study. Cross-sectional area values measured at the carpal tunnel inlet were included in the analyses. Results: Overall, 866 citations were retrieved and checked for eligibility. Finally, 16 articles were included for meta-analysis. These studies included a total sample of 2292 wrists including 776 mild, 823 moderate, and 693 severe carpal tunnel syndrome. The pooled analysis revealed a mean cross-sectional area of 11.64 mm 2 (95% confidence interval = 11.23–12.05 mm 2 , P < 0.001) for mild carpal tunnel syndrome, a mean cross-sectional area of 13.74 mm 2 (95% confidence interval = 12.59–14.89 mm 2 , P < 0.001) for moderate carpal tunnel syndrome, and a mean cross-sectional area of 16.80 mm 2 (95% confidence interval = 14.50–19.1 mm 2 , P < 0.001) for severe carpal tunnel syndrome. Conclusions: This is the first meta-analysis that provides the pooled median nerve cross-sectional area values in accordance with the electrodiagnostic classification of carpal tunnel syndrome severity. The values obtained in this study have clinical utility in ultrasonographic assessment of patients with carpal tunnel syndrome.

21 November 2014 in Neurological Research
Verified
Journal Article
Closed access
BEBina Eftekharsadat
Bina Eftekharsadat
ABArash Babaei-Ghazani
Arash Babaei-Ghazani
MMMehran Mohammadzadeh
Mehran Mohammadzadeh
MTMahnaz Talebi
Mahnaz Talebi
FEFariba Eslamian
Fariba Eslamian
EAElnaz Azari
Elnaz Azari
Balance and mobility impairments are common life-altering complications in patients with multiple sclerosis (MS). In this study, we aimed to investigate the efficacy of a short-term virtual reality (VR)-based balance training program on the balance ability of patients with MS. In this randomized controlled trial, 30 patients with relapsing-remitting or secondary-progressive MS were randomly assigned to an intervention or a control group. The intervention group performed a balance training program [postural stability training program (PST)] using the Biodex Balance System SD. Subjects in both groups were assessed using the manual muscle test (MMT), timed 'up and go' (TUG) test, the modified Ashworth scale, the Romberg test, the Berg balance scale (BBS), and the fall risk and postural stability tests, at baseline and after 12 weeks. The TUG, fall risk index (FRi), and overall stability index (OSI) were significantly improved in the intervention group after 24 sessions of balance training. The changes in TUG, Fri, and OSi indices in the intervention group were significantly higher than the control group. According to the fall risk and postural stability tests results, the VR-based balance training program could improve the balance ability of the patients with MS.

24 May 2018 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
ABArash Babaei-Ghazani
Arash Babaei-Ghazani
SNSaeedeh Najarzadeh
Saeedeh Najarzadeh
KMKorosh Mansoori
Korosh Mansoori
BFBijan Forogh
Bijan Forogh
SMSeyed Pezhman Madani
Seyed Pezhman Madani
BEBina Eftekharsadat
Bina Eftekharsadat

1 October 2018 in Journal of Pain Research
Verified
Journal Article
Open access
PDF file
SRSeyed Ahmad Raeissadat
Seyed Ahmad Raeissadat
ETElnaz Tabibian
Elnaz Tabibian
SRSeyed Mansoor Rayegani
Seyed Mansoor Rayegani
SRShahram Rahimi-Dehgolan
Shahram Rahimi-Dehgolan
ABArash Babaei-Ghazani
Arash Babaei-Ghazani
Purpose: This study aimed to review and pool the current literature on intra-articular ozone injection in knee osteoarthritis (OA) patients. Methods: A systematic review of three big databases was performed to identify all English-language randomized clinical trials (RCTs) that evaluated the efficacy of intra-articular ozone injection vs a control injection for knee OA sufferers, using the following two measuring tools: pain VAS and Western Ontario and McMaster Universities Arthritis Index (WOMAC). Results: A total of 428 patients in five RCTs were included, from which 53% (n=225) were in the ozone group and 47% in the control (hyaluronic acid [HA], dextrose, and air injection) group (n=203). The mean age of the patients in both groups was 64 years. Females were the majority. All studies had at least 2 months of follow-up (F/U). Mean difference (MD) between the groups for VAS in the first month was –0.23 with a P-value of 0.71 (negative value was in favor of ozone), whereas this difference in the third and sixth months reached 1.04 and 1.31, respectively, favoring the control group. These data demonstrated that control injection had a more prolonged pain relief period. A similar trend was seen regarding WOMAC scores; pooled results showed that ozone was slightly better than the control injections during the first month (MD =–7.84 [P=0.15]), but it declined to MD=2.55 and 8.23 at 2- to 3- and 4- to 6-month F/U, respectively, again in favor of control injections. Also, adverse events occurred homogeneously in both ozone (6/150 cases, 4%) and control groups (7/129 cases, 5.4%; P-value=0.31). Conclusion: Based on the current meta-analysis, intra-articular ozone injection efficacy was significantly superior to placebo and slightly lower to other control injections with non-significant difference. Therefore, ozone could be recommended as an efficient non-surgical treatment, durable for at least 3–6 months, in mild or moderate knee OA management.

5 July 2020 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
SESafoora Ebadi
Safoora Ebadi
NHNicholas Henschke
Nicholas Henschke
BFBijan Forogh
Bijan Forogh
NANoureddin Nakhostin Ansari
Noureddin Nakhostin Ansari
MTMaurits W van Tulder
Maurits W van Tulder
EFEhsan Fallah
Ehsan Fallah

1 April 2018 in Archives of Physical Medicine and Rehabilitation
Verified
Journal Article
Closed access
ABArash Babaei-Ghazani
Arash Babaei-Ghazani
PRPeyman Roomizadeh
Peyman Roomizadeh
BFBijan Forogh
Bijan Forogh
SMSeyed-Mohammad Moeini-Taba
Seyed-Mohammad Moeini-Taba
AAAmin Abedini
Amin Abedini
BEBina Eftekharsadat
Bina Eftekharsadat